{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:29:52Z","timestamp":1780090192542,"version":"3.54.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die aktinische Keratose (AK) ist ein epitheliales Carcinoma in situ der Haut. Aufgrund des Risikos einer malignen Transformation besteht ein fr\u00fchzeitiger Behandlungsbedarf. Gerade die initiale Therapie sollte neben der Wirksamkeit eine gute Vertr\u00e4glichkeit und Anwenderfreundlichkeit aufweisen. Kaliumhydroxid (KOH)-L\u00f6sung ist als keratolytische Behandlungsoption bei hyperkeratotischen Hauterkrankungen, wie z.\u202fB. Mollusca contagiosa, bereits etabliert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Wirksamkeit und Vertr\u00e4glichkeit von KOH-5\u202f%-L\u00f6sung zur Behandlung der leichten bis moderaten AK wurden in einer prospektiven, einarmigen, multizentrischen Medizinproduktestudie (Treatment of AK with KOH [TAKKOH]) untersucht. Die KOH-L\u00f6sung wurde 2\u2011mal t\u00e4glich \u00fcber 14\u00a0Tage aufgetragen mit anschlie\u00dfender Behandlungspause von 14\u00a0Tagen (\u2259\u00a01\u00a0Behandlungszyklus) f\u00fcr maximal 3\u00a0Behandlungszyklen oder mindestens bis zum Behandlungserfolg. Das prim\u00e4re Zielkriterium \u201eBehandlungserfolg\u201c wurde als komplette Remission (CR) aller AK-L\u00e4sionen eines Patienten definiert. Sekund\u00e4re Zielkriterien beinhalteten die Beurteilung der partiellen Remission (PR), der Anzahl an AK-L\u00e4sionen in Remission, die Wirksamkeitsbeurteilung anhand von Schulnoten durch Pr\u00fcf\u00e4rzte und Patienten sowie sicherheitsrelevante Endpunkte.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es wurden 73\u00a0Patienten in die Studie eingeschlossen. Eine CR wurde von 54,9\u202f% der Patienten erreicht, eine PR von 64,8\u202f% bei einer Reduktion der Gesamtzahl an L\u00e4sionen um 69,9\u202f%. Bei 46,6\u202f% der Patienten wurden unerw\u00fcnschte Ereignisse beobachtet. Diese \u00fcberwiegend unerw\u00fcnschten Wirkungen (82,6\u202f%) stellten ausnahmslos transiente und milde lokale Hautreaktionen dar.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die Studie liefert Hinweise auf die Wirksamkeit und Sicherheit von KOH-5\u202f%-L\u00f6sung zur l\u00e4sionsgerichteten topischen Therapie der AK.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-021-04888-0","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T09:02:53Z","timestamp":1628845373000},"page":"975-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Kaliumhydroxid-5\u202f%-L\u00f6sung bei aktinischer Keratose","Potassium hydroxide 5\u202f% solution in actinic keratosis"],"prefix":"10.1007","volume":"72","author":[{"given":"U.","family":"Reinhold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bai-Habelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Abeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Denfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dominicus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Radny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"4888_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/0019-5154.92675","volume":"57","author":"KI Al-Hamdi","year":"2012","unstructured":"Al-Hamdi\u00a0KI, Al-Rahmani\u00a0MA (2012) Evaluation of topical potassium hydroxide solution for treatment of plane warts. Indian J Dermatol 57:38\u201341","journal-title":"Indian J Dermatol"},{"key":"4888_CR2","unstructured":"ECHA Europa Potassium hydroxide \u2013 toxicological information. https:\/\/echa.europa.eu\/registration-dossier\/-\/registered-dossier\/15804\/7\/5\/1. Zugegriffen: 29. Sep. 2020"},{"key":"4888_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55040092","author":"A Balcere","year":"2019","unstructured":"Balcere A, Kupfere RM, Cema I et\u00a0al (2019) Prevalence, discontinuation rate, and risk factors for severe local site reactions with topical field treatment options for actinic keratosis of the face and scalp. Medicina. https:\/\/doi.org\/10.3390\/medicina55040092","journal-title":"Medicina"},{"key":"4888_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D De Berker","year":"2017","unstructured":"De Berker\u00a0D, Mcgregor\u00a0JM, Mohd Mustapa\u00a0MF et\u00a0al (2017) British association of dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol 176:20\u201343","journal-title":"Br J Dermatol"},{"key":"4888_CR5","first-page":"616","volume":"116","author":"R Gutzmer","year":"2019","unstructured":"Gutzmer\u00a0R, Wiegand\u00a0S, K\u00f6lbl\u00a0O et\u00a0al (2019) Actinic keratosis and cutaneous squamous cell carcinoma \u2013 treatment options. Dtsch Arztebl Int 116:616\u2013626","journal-title":"Dtsch Arztebl Int"},{"key":"4888_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0732-8893(90)90027-S","volume":"13","author":"DJ Haldane","year":"1990","unstructured":"Haldane\u00a0DJ, Robart\u00a0E (1990) A comparison of calcofluor white, potassium hydroxide, and culture for the laboratory diagnosis of superficial fungal infection. Diagn Microbiol Infect Dis 13:337\u2013339","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4888_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","volume":"62","author":"CW Hanke","year":"2010","unstructured":"Hanke\u00a0CW, Beer\u00a0KR, Stockfleth\u00a0E et al (2010) Imiquimod 2.5\u202f% and 3.75\u202f% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3\u2011week cycles. J\u00a0Am Acad Dermatol 62:573\u2013581","journal-title":"J Am Acad Dermatol"},{"key":"4888_CR8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/ijd.12505","volume":"53","author":"S Isik","year":"2014","unstructured":"Isik\u00a0S, Koca\u00a0R, Sarici\u00a0G et al (2014) A comparison of a\u00a05\u202f% potassium hydroxide solution with a\u00a05-fluorouracil and salicylic acid combination in the treatment of patients with anogenital warts: a\u00a0randomized, open-label clinical trial. Int J Dermatol 53:1145\u20131150","journal-title":"Int J Dermatol"},{"key":"4888_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen\u00a0MHE, Kessels\u00a0J, Nelemans\u00a0PJ et\u00a0al (2019) Randomized trial of four treatment approaches for actinic keratosis. N\u00a0Engl J Med 380:935\u2013946","journal-title":"N Engl J Med"},{"key":"4888_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1055\/s-2007-966517","volume":"33","author":"T Jansen","year":"2007","unstructured":"Jansen\u00a0T, Romiti\u00a0R, Dissemond\u00a0J et\u00a0al (2007) Evaluation of the efficacy and tolerability of 5\u202f% potassium hydroxide solution in the treatment of molluscum contagiosum in childhood. Akt Dermatol 33:210\u2013215","journal-title":"Akt Dermatol"},{"key":"4888_CR11","first-page":"335","volume":"70","author":"J Jorizzo","year":"2002","unstructured":"Jorizzo\u00a0J, Stewart\u00a0D, Bucko\u00a0A et al (2002) Randomized trial evaluating a\u00a0new 0.5\u202f% fluorouracil formulation demonstrates efficacy after 1\u2011, 2\u2011, or 4\u2011week treatment in patients with actinic keratosis. Cutis 70:335\u2013339","journal-title":"Cutis"},{"key":"4888_CR12","series-title":"Langversion 1.0 032\/022OL","volume-title":"S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut","author":"L Onkologie","year":"2018","unstructured":"Onkologie\u00a0L (2018) S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut. Langversion 1.0 032\/022OL"},{"key":"4888_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","volume":"151","author":"H Pomerantz","year":"2015","unstructured":"Pomerantz\u00a0H, Hogan\u00a0D, Eilers\u00a0D et al (2015) Long-term efficacy of topical fluorouracil cream, 5\u202f%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 151:952\u2013960","journal-title":"JAMA Dermatol"},{"key":"4888_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/jdv.13935","volume":"31","author":"U Reinhold","year":"2017","unstructured":"Reinhold\u00a0U, Hadshiew\u00a0I, Melzer\u00a0A et al (2017) Low-dose 5\u2011fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and\/or forearms \u2013 results of a\u00a0non-interventional study. J\u00a0Eur Acad Dermatol Venereol 31:455\u2013462","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4888_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1525-1470.2000.01837-7.x","volume":"17","author":"R Romiti","year":"2000","unstructured":"Romiti\u00a0R, Ribeiro\u00a0AP, Romiti\u00a0N (2000) Evaluation of the effectiveness of 5\u202f% potassium hydroxide for the treatment of molluscum contagiosum. Pediatr Dermatol 17:495","journal-title":"Pediatr Dermatol"},{"key":"4888_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1525-1470.2006.00235.x","volume":"23","author":"KA Short","year":"2006","unstructured":"Short\u00a0KA, Fuller\u00a0LC, Higgins\u00a0EM (2006) Double-blind, randomized, placebo-controlled trial of the use of topical 10\u202f% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatr Dermatol 23:279\u2013281","journal-title":"Pediatr Dermatol"},{"key":"4888_CR17","first-page":"459","volume":"144","author":"E Stockfleth","year":"2009","unstructured":"Stockfleth\u00a0E (2009) Topical management of actinic keratosis and field cancerisation. G\u00a0Ital Dermatol Venereol 144:459\u2013462","journal-title":"G Ital Dermatol Venereol"},{"key":"4888_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth\u00a0E, Kerl\u00a0H, Zwingers\u00a0T et al (2011) Low-dose 5\u2011fluorouracil in combination with salicylic acid as a\u00a0new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101\u20131108","journal-title":"Br J Dermatol"},{"key":"4888_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson\u00a0N, Abramovits\u00a0W, Berman\u00a0B et al (2010) Imiquimod 2.5\u202f% and 3.75\u202f% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2\u2011week cycles. J\u00a0Am Acad Dermatol 62:582\u2013590","journal-title":"J Am Acad Dermatol"},{"key":"4888_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/CIA.S31930","volume":"8","author":"EE Uhlenhake","year":"2013","unstructured":"Uhlenhake\u00a0EE (2013) Optimal treatment of actinic keratoses. Clin Interv Aging 8:29\u201335","journal-title":"Clin Interv Aging"},{"key":"4888_CR21","volume-title":"OECD SIDS \u2013 Potassium hydroxide CAS No.: 1310-58-3","author":"P Unep","year":"2001","unstructured":"Unep\u00a0P (2001) OECD SIDS \u2013 Potassium hydroxide CAS No.: 1310-58\u20113"},{"key":"4888_CR22","doi-asserted-by":"publisher","first-page":"e96829","DOI":"10.1371\/journal.pone.0096829","volume":"9","author":"S Vegter","year":"2014","unstructured":"Vegter\u00a0S, Tolley\u00a0K (2014) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. Plos One 9:e96829","journal-title":"Plos One"},{"key":"4888_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bjd.12420","volume":"169","author":"RN Werner","year":"2013","unstructured":"Werner\u00a0RN, Sammain\u00a0A, Erdmann\u00a0R et\u00a0al (2013) The natural history of actinic keratosis: a\u00a0systematic review. Br J Dermatol 169:502\u2013518","journal-title":"Br J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04888-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04888-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04888-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T20:47:31Z","timestamp":1634935651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04888-0"}},"subtitle":["Ein neuer Therapieansatz zur l\u00e4sionsgerichteten Behandlung","A\u00a0novel therapeutic approach in the lesion-directed treatment"],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4888"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04888-0","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"4 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Reinhold, D.\u00a0Abeck, R.\u00a0Dominicus und T.\u00a0Fischer sind als Berater f\u00fcr die Firma InfectoPharm Arzneimittel und Consilium GmbH t\u00e4tig. R.\u00a0Denfeld, J.\u00a0Bai-Habelski und P.\u00a0Radny geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}